Organization | Blood and Marrow Transplant Clinical Trials Network

Blood and Marrow Transplant Clinical Trials Network Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Rockville MD United States (2001)

Organization Overview

First Clinical Trial

2001

NCT00023530

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Blood and Marrow Transplant Clinical Trials Network

Active Ingredients

Drugs in Phase 3 Trials (36)

allogeneic cord blood (1 trial)

allogeneic stem cells (1 trial)

allogenic autologous bone marrow ctl (1 trial)

alpha-1 antitrypsin (Prolastin) (1 trial)

autologous cd34+ cells (1 trial)

autologous hematopoietic cell (1 trial)

autologous mononuclear stem cell (3 trials)

autologous umbilical cord blood (2 trials)

bone marrow cells (1 trial)

bortezomib (velcade) (3 trials)

busulfan (myleran) (4 trials)

carmustine (bicnu) (2 trials)

cyclophosphamide (cytoxan) (10 trials)

cyclosporine (sandimmune) (2 trials)

etanercept (enbrel) (2 trials)

fluconazole (diflucan) (2 trials)

fludarabine (fludara) (10 trials)

gilteritinib (1 trial)

hla-matched related donor bone marrow (2 trials)

lenalidomide (revlimid) (3 trials)

melphalan (alkeran) (5 trials)

methotrexate (2 trials)

mycophenolate (myfortic) (5 trials)

naltrexone (revia) (4 trials)

peripheral blood hematopoietic cell (1 trial)

prednisone (meticorten) (2 trials)

rituximab (rituxan) (2 trials)

ruxolitinib (jakafi) (1 trial)

sargramostim (leukine) (3 trials)

sirolimus (rapamune) (6 trials)

stem cells (1 trial)

tacrolimus (prograf) (8 trials)

thalidomide (Thalomid) (2 trials)

tositumomab (bexxar) (1 trial)

urea (3 trials)

voriconazole (vfend) (2 trials)

Drugs in Phase 2 Trials (18)

allogeneic hematopoietic stem cells (Hemacord) (5 trials)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (4 trials)

autologous bone marrow derived cd34+ hsc cells transduced with the lentiviral vector containing a short-hairpin rna targeting bcl11a (1 trial)

bone marrow derived mesenchymal stem cells (2 trials)

cord blood hematopoietic stem cell (1 trial)

cytarabine (cytosar-u) (1 trial)

dendritic cell tumor fusion vaccine (1 trial)

denileukin diftitox (ontak) (1 trial)

etoposide (vepesid) (1 trial)

haploidentical stem cell (1 trial)

hydroxyurea (hydrea) (1 trial)

ixazomib (ninlaro) (1 trial)

k-nk002 (1 trial)

maraviroc (selzentry) (1 trial)

mesna (mesnex) (1 trial)

pentostatin (nipent) (1 trial)

thiotepa (1 trial)

tresulfan (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Anemia, Sickle Cell (Phase 2)

Burkitt Lymphoma (Phase 3)

Communicable Diseases (Phase 3)

Epstein-Barr Virus Infections (Phase 2)

Graft vs Host Disease (Phase 3)

Granulomatous Disease, Chronic (Phase 2)

Immune System Diseases (Phase 2)

Immunologic Deficiency Syndromes (Phase 2)

Infections (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphohistiocytosis, Hemophagocytic (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Multiple Myeloma (Phase 3)

Mycoses (Phase 3)

Myelodysplastic-Myeloproliferative Diseases (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Plasmablastic Lymphoma (Phase 3)

Pneumonia (Phase 3)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Tissue Adhesions (Phase 2)

Virus Diseases (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 39
# of Trial APIs: 54